Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

Overview

This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.

Full Title of Study: “Regulatory Post-Marketing Surveillance (rPMS) of Xolair® (Xolair® 150mg Powder for Solution for Injection, Xolair® 150mg/1ml Liquid in Pre-filled Syringe, Xolair® 75mg/0.5ml Liquid in Pre-filled Syringe) for Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 31, 2025

Detailed Description

This is a 24-week, prospective, open-label, multi-center, single-arm, observational, post-marketing surveillance study under routine clinical practice and does not impose a therapy, visit, or assessment. The study design was approved by the Korean health authority. The purpose of this study is not to answer scientific hypotheses, but to describe the incidences of all potential adverse events (AEs), serious adverse events (SAEs), and unexpected AEs not listed in the local label information occurring in Korean patients under routine clinical practice following the approved local label information.

Interventions

  • Other: Xolair
    • There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.

Arms, Groups and Cohorts

  • Xolair
    • patients who prescribed with Xolair according to the current label information in Korea.

Clinical Trial Outcome Measures

Primary Measures

  • Incidences of adverse events/adverse drug reactions (AEs/ADRs)
    • Time Frame: Up to 24 weeks
    • Incidences of adverse events/adverse drug reactions (AEs/ADRs), serious AEs/ADRs (SAEs/SADRs), unexpected AEs/ADRs (UAEs/UADRs), serious unexpected AEs/ADRs (SUAEs/SUADRs) will be collected

Secondary Measures

  • Change from baseline in SNOT-22
    • Time Frame: Baseline, Week 12 and Week 24
    • Sino-Nasal Outcome Test-22 (SNOT-22) is a validated questionnaire that is used to assess the impact of chronic rhinosinusitis on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life.
  • Incidences of AEs by subject characteristics
    • Time Frame: Up to 24 weeks
    • The incidences of AEs by subject characteristics (demographic and other baseline information, Xolair® administration status, concomitant medication and therapy, etc.). The significance of the difference in the incidence of adverse events between categories within each characteristic will be tested using the Chi-square test or Fisher’s exact test.
  • Subject characteristics that affect the occurrence of adverse events
    • Time Frame: Up to 24 weeks
    • Logistic regression analysis will be performed to analyze subject characteristics that affect the occurrence of adverse events.
  • change from baseline in SNOT-22 according to subject characteristics
    • Time Frame: Week 12 and Week 24
    • Change from baseline in SNOT-22 according to subject characteristics (demographic and other baseline information, Xolair® administration status, concomitant medication and therapy, etc.). The statistical significance of the difference in the change between the groups will be tested by two-sample t-test, Wilcoxon rank sum test, ANOVA, or Kruskal-Wallis test.
  • Subject characteristics that affect the change from baseline in SNOT-22
    • Time Frame: Week 12 and Week 24
    • Multivariate linear regression analysis will be performed to evaluate the subject characteristics (demographic and other baseline information, Xolair® administration status, concomitant medication and therapy, etc.) that affect the change from baseline in SNOT-22

Participating in This Clinical Trial

Inclusion Criteria

1. Adults aged ≥18 years 2. Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS) 3. Patients prescribed with Xolair® as per the locally approved label information. 4. Patients who provide written informed consent to participate in the study Exclusion Criteria:

1. Patients who do not provide consent to participate in the study 2. Patients participating in other clinical trial 3. Contraindications listed in the locally approved label information of Xolair®

  • Hypersensitivity to the active ingredient or any other ingredient of Xolair® – Patients with myocardial infarction or history of myocardial infarction (pre-filled syringes only)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Novartis Pharmaceuticals
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Novartis Pharmaceuticals, Study Director, Novartis Pharmaceuticals
  • Overall Contact(s)
    • Novartis Pharmaceuticals, +41613241111, novartis.email@novartis.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.